Taysha Gene Therapies: Promising FDA Alignment and Strong Financials Justify Buy Rating

Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report) and keeping the price target at $7.50.

Yanan Zhu has given his Buy rating due to a combination of factors that highlight Taysha Gene Therapies’ promising outlook. The company’s alignment with the FDA on the pivotal study design is seen as a significant positive development, as it sets the stage for the upcoming pivotal study and the anticipated high dose data readout. This alignment with the FDA, including agreement on primary endpoints and study population, suggests a streamlined path forward for the company’s clinical trials.
Additionally, Taysha Gene Therapies reported a better-than-expected financial performance for the first quarter of 2025, with a net loss per share of $0.08 compared to the consensus estimate of $0.09. The company’s robust cash position, which is projected to support operations into the fourth quarter of 2026, further strengthens its financial stability. These factors, combined with the company’s proactive steps in finalizing and submitting the study protocol and statistical analysis plan, contribute to the optimistic outlook and justify the Buy rating.

Zhu covers the Healthcare sector, focusing on stocks such as Regulus, uniQure, and Sarepta Therapeutics. According to TipRanks, Zhu has an average return of -8.9% and a 26.79% success rate on recommended stocks.

In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $5.00 price target.